DeepLife — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

DeepLife, founded in 2019 in Paris, is a private, pre-revenue biotech company pioneering a causal AI platform to build digital twins of cells. The platform uses multi-omics data to simulate disease at the single-cell level, aiming to drastically reduce target discovery timelines and improve the low success rates of traditional drug development. With a highly educated team of around 25 employees, the company is developing its own internal pipeline while likely seeking platform partnerships with larger pharmaceutical firms.

AI / Machine LearningDrug Discovery

Technology Platform

AI-powered platform integrating multi-omics data and causal AI to create digital twins of cells for simulating disease and predicting drug responses.

Opportunities

The growing demand for AI-driven R&D solutions in pharma presents a large market for DeepLife's platform.

Successfully validating their digital twin approach could allow them to secure lucrative partnerships and build a high-value internal pipeline, particularly in drug repositioning.

Risk Factors

Key risks include the technical challenge of creating biologically accurate digital twin models that translate to real-world outcomes, intense competition in the AI drug discovery space, and dependence on venture funding as a pre-revenue company.

Competitive Landscape

DeepLife operates in the competitive AI/ML drug discovery sector, competing with firms like Recursion, Exscientia, and Insilico Medicine. Its differentiation is a focused emphasis on causal AI and single-cell digital twins, a specialized niche within the broader field.

More companies in AI / Machine Learning →More companies in France →